^
Association details:
| Biomarker: | BRAF V600E + PD-L1 expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
422 - Sequential targeted therapy and immunotherapy of a BRAF positive metastatic melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a novel PD-1 antibody Sintilimab
Published date:
03/10/2021
Excerpt:
A 75-year old male patient presented...a nodular malignant melanoma...NGS sequencing of the tumor revealed the canonical BRAF V600E mutation....He received vemurafenib at a dose of 480 mg bid combined with cobimetinib 60mg...the treatment was ongoing till disease progression in April 2020. Immunohistochemical analysis of the biopsy specimen demonstrated PD-L1 expression in 4% of tumor cells and immunotherapy was chosen as the third-line therapy.... the patient started off-label use of Sintilimab and achieved partial response.
